Edition:
India

Cellectar Biosciences Inc (CLRB.OQ)

CLRB.OQ on NASDAQ Stock Exchange Capital Market

2.16USD
9:35pm IST
Change (% chg)

$0.03 (+1.41%)
Prev Close
$2.13
Open
$2.16
Day's High
$2.16
Day's Low
$2.15
Volume
4,724
Avg. Vol
73,619
52-wk High
$4.25
52-wk Low
$1.22

Latest Key Developments (Source: Significant Developments)

Cellectar Receives FDA Fast Track Designation For Experimental Lymphoma Drug
Tuesday, 9 Jul 2019 

July 9 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR RECEIVES FDA FAST TRACK DESIGNATION FOR CLR 131 IN DIFFUSE LARGE B-CELL LYMPHOMA.  Full Article

North Sound Trading LP Reports A 9.0% Passive Stake In Cellectar Biosciences Inc
Saturday, 29 Jun 2019 

June 28 (Reuters) - Cellectar Biosciences Inc ::NORTH SOUND TRADING LP REPORTS A 9.0% PASSIVE STAKE IN CELLECTAR BIOSCIENCES INC AS OF JUNE 20, 2019 - SEC FILING.  Full Article

Cellectar Biosciences Announces $10.0 Million Financing
Thursday, 16 May 2019 

May 16 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR BIOSCIENCES ANNOUNCES $10.0 MILLION FINANCING.CELLECTAR - AGREEMENTS WITH INSTITUTIONAL INVESTORS TO PURCHASE APPROXIMATELY $5.0 MILLION IN A REGISTERED DIRECT OFFERING OF 2 MILLION COMMON SHARES.CELLECTAR - AGREEMENTS WITH INSTITUTIONAL INVESTORS TO ALSO PURCHASE ABOUT $5.0 MILLION IN A CONCURRENT PRIVATE PLACEMENT OF 2 MILLION COMMON SHARES.CELLECTAR BIOSCIENCES INC - INTENDS TO USE NET PROCEEDS FROM OFFERING FOR RESEARCH AND DEVELOPMENT, FUNDING CLINICAL STUDIES.  Full Article

Cellectar Biosciences Q1 Loss Per Share $0.76
Monday, 6 May 2019 

Cellectar Biosciences Inc ::CELLECTAR REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.Q1 LOSS PER SHARE $0.76.CELLECTAR - REPORTED POSITIVE TOP-LINE RESULTS FROM RELAPSED/REFRACTORY MULTIPLE MYELOMA COHORT IN ONGOING PHASE 2 CLINICAL STUDY OF CLR 131.AS OF MARCH 31, 2019, CASH AND CASH EQUIVALENTS WERE APPROXIMATELY $10.5 MILLION VERSUS $13.3 MILLION AS OF DECEMBER 31, 2018.CELLECTAR BIOSCIENCES - BELIEVES CASH BALANCE IS ADEQUATE TO FUND OUR PIPELINE DEVELOPMENT AND OPERATIONS INTO Q1 2020.  Full Article

Cellectar reports third quarter results
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $1.65.  Full Article

Cellectar Biosciences Appoints Brian M. Posner As Chief Financial Officer
Wednesday, 4 Apr 2018 

April 4 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR BIOSCIENCES APPOINTS BRIAN M. POSNER AS CHIEF FINANCIAL OFFICER.POSNER JOINS CELLECTAR FROM ALLIQUA BIOMEDICAL, WHERE HE WAS CHIEF FINANCIAL OFFICER.  Full Article

Cellectar Reports 2017 Financial Results
Thursday, 22 Mar 2018 

March 21 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR REPORTS 2017 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.CELLECTAR BIOSCIENCES INC - ‍CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2017 WERE ABOUT $10.0 MILLION​.CELLECTAR BIOSCIENCES INC - MANAGEMENT BELIEVES THAT CURRENT CASH AND CASH EQUIVALENTS ARE SUFFICIENT TO FUND BUDGETED OPERATIONS INTO Q1 OF 2019.  Full Article

Cellectar Biosciences On Jan 3, Notified Affected Employees Of Its Plan To Reduce Its Workforce By 6 Positions
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR BIOSCIENCES - ON JAN 3, NOTIFIED AFFECTED EMPLOYEES OF ITS PLAN TO REDUCE ITS WORKFORCE BY 6 POSITIONS -SEC FILING.CELLECTAR BIOSCIENCES-TO RECORD NON-CASH EXPENSES OF ABOUT $1.2 MILLION IN QUARTER ENDED DEC 31 & CASH COSTS OF ABOUT $0.2 MILLION IN 2018, RELATING TO SHUTDOWN.CELLECTAR BIOSCIENCES - IN JAN 2018, CO BEGAN IMPLEMENTING SHUTDOWN OF ITS MANUFACTURING OPERATIONS AT CO'S HEADQUARTERS IN MADISON, WISCONSIN.  Full Article

Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial of CLR 131
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR ANNOUNCES EXPANSION OF RELAPSED/REFRACTORY MULTIPLE MYELOMA COHORT IN PHASE 2 TRIAL OF CLR 131.CELLECTAR BIOSCIENCES - WILL INCREASE TARGETED PATIENT ENROLLMENT IN R/R MULTIPLE MYELOMA COHORT OF CO'S CURRENTLY ENROLLING CLR 131 PHASE 2 CLINICAL TRIAL.  Full Article

Cellectar Biosciences posts Q3 loss of $0.26 per share
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences reports third quarter 2017 financial and corporate performance.Q3 loss per share $0.26.Cash and cash equivalents as of September 30, 2017 were about $5.7 million​.  Full Article